One hundred fourteen patients suffering from neuropsychiatric conditions have been studied using 99ffiTc-Iabeled hexamethylpropyleneamine oxime (HM PAO) and single photon emission computed tomography (SPECT). Ninety-one patients had a firm clinical diagno sis while 23 were examined without knowledge of the clinical diagnosis. Of the 91 patients, 51 were suffering from dementia, 25 multi-infarct type and 26 Alzheimer's disease. In 19 of the Alzheimer's patients, a characteristic pattern of decreased perfusion in the parieto-occipital re gions was demonstrated while those with multi-infarct type showed varying degrees of irregular uptake in the cerebral cortex. These appearances are similar to those shown with positron emission tomography (PET) and we believe that HM-PAO will provide a widely available method for identifying patients with Alzheimer's disease. Twenty-nine patients were suffering from diseases in-
The development of hexamethylpropyleneamine oxime (HM-PAO), which, when labelled with tech netium-99m, has been shown to be a suitable agent for visualizing regional cerebral blood flow (Sharp et al., 1986) , has offered the prospect of routine cerebral imaging of patients with psychiatric dis eases.
Preliminary studies have shown good correlation between the findings using iodine-123-labeled iso propylamphetamine and HM-PAO in patients with dementia (Gemmell et al., 1986) and show consid erable promise for differentiating Alzheimer's dis ease from other forms of dementia Smith et al., 1987) .
It is important when assessing any new radio-S116 volving the basal ganglia. Fifteen patients with Parkin son's disease showed no significant abnormality in basal ganglia uptake, while 7 or 8 patients with Huntington's disease who had full examinations showed decreased up take in the caudate nuclei. Similarly, four of six patients with other basal ganglia diseases showed impaired uptake by basal ganglia, and it is concluded that HM-PAO may be useful for the diagnosis and management of this type of patient. Twenty-three patients received HM-PAO imag ing as part of their diagnostic work-up; in 19 of them, detailed follow-up was obtained, which indicated that in 7 cases the result of the HM-PAO scan altered the clinical diagnosis and in 9 cases resulted in a change in manage ment. In the remaining 13 cases, the study was found to be helpful in confirming the diagnosis. Key Words:
[99ffiTc]-HM-PAO-SPECT-Dementia-Alzheimer's disease.
pharmaceutical to ascertain not only the character istic appearances of different disease states, but also where the new diagnostic technique will be useful for patient management. To this end, two categories of patient have been studied: those in whom a clinical diagnosis had been made, and a smaller group who were imaged as part of the diag nostic process. This second group was followed by questionnaire to the referring psychiatrist in an ef fort to ascertain any influence that the HM-PAO scan result may have had on the diagnosis or man agement of the patient.
PATIENTS AND METHODS
Seven normal healthy volunteers and 114 patients suf fering from a variety of psychiatric diseases have been studied ( Table 1) . The ages of the volunteers ranged from 25-75 years, with a mean age of 35.8 years, and of the patients from 25-87 years, with a mean age of 66.2 years.
All of the patients were examined by single photon The data were collected using a high resolution collima tor, except when the count rate was found to be below 2000 cps, in which case a general purpose collimator would be employed. The resolution obtained using the high resolution collimator is 8-10 mm and with the gen eral purpose collimator it is 15-20 mm. From the collected data, 12 axial sections of the brain were constructed parallel to the orbitomeatal line. Each section was 10 mm thick and contiguous with its neigh bors. The image data were acquired on a 64 x 64 matrix and interpolated at 256 x 256 for display. No quantitation of regional cerebral blood flow was attempted.
Each set of 12 sections was presented as both gray scale (256 levels) and color (16 levels) images, to be read by two observers independently before making a consen sus report. This report was then correlated with the clin-ical diagnosis by a third person. The clinical diagnosis was made using the 3rd Edition of the Diagnostic and Statistical Manual of the American Psychiatric Associa tion and the Hachinski Ischaemia Score (Hachinski et aI., 1975) .
RESULTS

Normal
Seven normal volunteers aged between 25-75 years (mean of 38.5 years) were imaged. The distri bution of activity in these volunteers was seen to be symmetrical in both cerebral hemispheres, being greatest in a strip of cortex along the cortex along the convexity of the frontal, parietal, temporal, and occipital lobes, corresponding to the anatomical distribution of gray matter. Activity was also high in the region of the basal ganglia. The area between the cortex and the basal ganglia, corresponding to the white matter, had less HM-PAO activity. The contour of the cortical activity was undulating and contained depressions corresponding to the inter hemispheric and Sylvian fissures ( Fig. 1 ).
Fifty-one patients suffering from dementia have been studied with [ 99 ffiTc]_HM_PAO. This group was divided according to Hachinski scores (Hachinski et aI., 1975) into 26 having dementia of the Alzheimer's type (DAT) (score <7) and 25 hav ing multi-infarct dementia (MID) (score >7). None of the patients was severely handicapped. The age range for the DAT group was 58--79 years, with a mean of 64.6 years, and that for the MID group was 46-87 years, with a lot of 67.8 years.
Two distinct patterns of uptake of HM-PAO have
been recognized correlating with the clinical diag nosis. In 19 of the 26 patients classified as having DAT, bilateral parieto-occipital decreased uptake was demonstrated (Fig. 2) , and in 7 there were also deficits in perfusion in the frontoparietal region. In all cases, perfusion of the basal ganglia appeared normal. In only two cases was there any evidence of any small focal area of absent perfusion consis tent with infarction, which correlated with X-ray CT. The pattern of uptake in the 25 patients with MID varied from normal, in the less severely im paired, to mUltiple perfusion deficits in both corti ces with no distinctive pattern (Fig. 3) . In three of the MID patients, bilateral parieto-occipital perfu sion deficits were present that correlated with areas of infarction on X-ray CT. Thirteen of the MID pa tients showed evidence of small infarcts on X-ray CT while only 2 in the DAT group did. The appearances obtained using HM-PAO in the patients suffering from DAT are the same as those described with positron emission tomography (PET) using [ ,s F]fluorodeoxyglucose (Friedland et aI., 1983) and SPECT using [ 123 I]-Isopropyl amphetamine (IMP) (Cohen et aI., 1986; Gemmell et aI., 1986) .
Twenty-three patients who were referred for HM-PAO imaging as part of their diagnostic work up (Table 1) were followed by questionnaire to the referring clinician. Answers to questions on diagno sis at the time of referral, final diagnosis, changes in patient management, and clinical usefulness were obtained in 19/23 patients. All 19 patients were re-ferred for diagnostic help as part of their man agement. Their previous investigations included Hachinski Ischaemia Score (Hachinski et aI., 1975) , Mental Status Questionnaire (Wilson and Brass, 1973) , Katzman Memory Orientation Concentration test (Katzman et aI., 1983) , Dementia Check List (Hare, 1978) , and a full clinical examination. X-ray CT scans were performed on all of the patients sub sequent to the HM-PAO scan.
In 7 of the 19 patients, the findings of the HM PAO study resulted in a change of working diagno sis and in 9 a change of management. In the remain ing 12 patients, the investigation was considered to have been useful, confirming the initial diagnosis. The main reason for referral in this group of 14/19 patients was to exclude or confirm MID and the presence of cerebral infarcts, which were subse quently confirmed by X-ray CT, in patients suffer ing from depression. Seven of 14 patients suspected of having MID showed a normal regional cerebral blood flow pattern and were thereafter treated as suffering from depression alone. The other reason was to investigate 5 of 19 patients with long standing disease that was either following an atyp ical course or had changed suddenly. Two of five patients had a diagnosis of MID changed to DAT while the other three had confirmation of their di agnosis, two with MID and one with DAT. The principal management considerations were to ex clude infarction in patients with depression prior to electroconvulsive therapy and for the planning of long-term accommodation. 
Schizophrenia
Seven patients aged 30-64 years (mean age of 52.3 years) suffering from schizophrenia have been studied. In all cases, the distribution of HM-PAO within the cerebral gray matter was found to be normal.
Parkinson's disease
Fifteen patients suffering from Parkinson's dis ease, a condition characterised by a coarse invol untary intention tremor for which they require hos pitalization and treatment with L-Dopa, have been studied. Seven patients had no evidence of intellec tual impairment, while eight were considered to have features of dementia.
All but one of the patients were receiving treat ment with L-Dopa; no characteristic appearance was seen in any of the patients, and especially the pattern did not resemble that seen in DAT. Two of the seven nondementing patients and six of the de menting patients showed evidence of patchy under perfusion of the cerebral cortex predominantly in the parietal and posterior frontal cortex. Five of the seven nondementing and two of the eight dementing patients showed the normal appearance of HM PAO uptake. No characteristic changes in the up take pattern in the basal ganglia were observed. One patient showed a significantly decreased up take in all of the basal ganglia and another a de creased uptake in the right thalamus. The remainder were considered to be normal. These findings are not consistent with the findings of some other work ers, who have found varying degrees of underper-fusion in the basal ganglia of patients with Parkin son's disease (Borsato et al., 1987) . The fact that the patients were receiving treatment at the time of scanning may account for the normal appearance of the basal ganglia, since it has been reported that changes in perfusion of the basal ganglia occur when L-Dopa treatment is withdrawn (Costa et aI., 1987) .
Huntington's disease
Eight patients suffering from Huntington's dis ease, an inherited condition characterised by a slowly progressive dementia and continuous invol untary choreiform movements, have been studied. Their ages ranged from 27-86 years, with a mean age of 57.1 years. Seven of the patients had a family history of the disease, choreiform movements, and varying degrees of cognitive impairment. In six, a full SPECT examination was completed, but in one with severe movement disorder the examination was not completed due to patient movement. The HM-PAO appearance in these six patients showed a significant decrease in uptake in the caudate nuclei that was matched by corresponding caudate atro phy seen on magnetic resonance imaging (MRI) (Fig. 4) . However, the size of the deficit seen with HM-PAO is much larger than can be accounted for by ventricular enlargement alone (Fig. 5 ). Varying degrees of reduced cerebral perfusion were noted in four of the patients.
The eighth patient, a 35-year-old female whose mother had suffered from Huntington's disease prior to her death, presented with a depressive iIl- ness. She was studied by both HM-PAO and MRI. The HM-PAO scan showed the characteristic ap pearances of Huntington's disease with bilateral caudate nucleus diminished perfusion, but her MRI images showed no evidence of ventricular dilatation or of caudate atrophy. While this patient, who is "at risk" of developing Huntington's disease, cannot strictly be considered to be pre symptomatic be cause she exhibits some affective symptoms, it is of A 8 interest to note that she shows similar appearance to that seen in established Huntington's disease. It is likely that HM-PAO is able to demonstrate pre symptomatic involvement of the caudate nucleus before any structural change is evident with X-ray CT or MRI, in a similar way that PET scanning using fluorodeoxyglucose has been shown to (Mazziotta et al., 1987) .
Other conditions involving the basal ganglia
In the miscellaneous group of ten patients were six who were suffering from other diseases involv ing the basal ganglia. One patient, a young man suf fering from the Gilles de la Tourette syndrome and exhibiting multiple involuntary tics, showed no ab normality on the HM-PAO images. Another with spasmodic left-sided torticollis showed a significant decrease in uptake in the region of the right thala-. mus. A 53-year-old woman who had been receiving phenelzine for the treatment of depression devel oped right-sided hemibalismus and when examined with HM-PAO demonstrated increased uptake in the left thalamus and caudate nucleus (Fig. 6) .
Two patients had conditions that showed gross structural abnormality on X-ray CT. One was a 27year-old man suffering from Fahr's disease who showed gross basal ganglia calcification on X-ray CT and decreased uptake of HM-PAO in the basal ganglia. A 23-year-old woman suffering from Wil- The sixth patient was a retired professional boxer who suffered from involuntary movements. His HM-PAO scan showed no significant change in basal ganglia and patchy cerebral uptake in keeping with a multi-infarct type of dementia.
CONCLUSION
From the study of this series of patients, it ap pears that the use of HM-PAO imaging can differ entiate two distinct types of dementia. This obser vation indicates that HM-PAO can be used for dif ferentiating between DAT and MID based upon the presence or absence of the characteristic parieto occipital perfusion deficits, raising the possibility of a positive feature for the diagnosis of DAT. Be cause HM-PAO is labeled with technetium-99m, it can be made available to a wider population than IMP or PET imaging, being available in all Nuclear Medicine Departments equipped with a tomo graphic gamma camera.
HM-PAO imaging should prove useful for aiding in the positive diagnosis of DAT as well as for dif ferentiating it from other dementias. It will also be useful in the management of the elderly depressed FIG. 6. Decreased uptake in the left thala mus and caudate nucleus in a patient with hemibalismus. patient, to exclude the presence of cerebral infarc tion when planning electroconvulsive therapy.
In the management of patients with Huntington's disease, HM-PAO has been shown to demonstrate caudate underperfusion. It seems likely that HM PAO may provide a widely available method for studying altered caudate function in Huntington's disease by following blood flow related abnormali ties.
At present, it appears that the use of HM-PAO for studying patients with Parkinson's disease is of limited value, but further work is necessary to clar ify its use in this group of patients. Similarly, more patients suffering from diseases of the basal ganglia must be studied to assess the full potential of HM P AO for the diagnosis and management of these patients.
We believe that HM-PAO imaging should prove useful in the management of a wide range of neuro psychiatric patients, often by confirming the clinical diagnosis, but also by contributing to patient man agement in many cases.
